Amicogen Valuation

Is A092040 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A092040 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A092040's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A092040's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A092040?

Key metric: As A092040 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A092040. This is calculated by dividing A092040's market cap by their current revenue.
What is A092040's PS Ratio?
PS Ratio	1.3x
Sales	₩158.98b
Market Cap	₩203.09b

A092040 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.5x
Enterprise Value/EBITDA	47.8x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does A092040's PS Ratio compare to its peers?

The above table shows the PS ratio for A092040 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	18.7x
A304360 S.Biomedics	22.4x	n/a	₩266.6b
A083790 CG Invites	35.9x	n/a	₩199.9b
A138610 NIBEC	7.7x	n/a	₩150.1b
A166480 CORESTEMCHEMON	8.9x	n/a	₩270.9b
A092040 Amicogen	1.3x	n/a	₩203.1b

Price-To-Sales vs Peers: A092040 is good value based on its Price-To-Sales Ratio (1.3x) compared to the peer average (18.7x).

Price to Sales Ratio vs Industry

How does A092040's PS Ratio compare vs other companies in the KR Biotechs Industry?

26 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	9.2x	35.0%
A092040 Amicogen	1.3x	n/a	US$144.60m
A006280 GC Biopharma	0.9x	9.0%	US$1.09b
A096530 Seegene	2.7x	15.7%	US$758.40m

26 Companies		Estimated Growth	Market Cap
Industry Avg.	9.2x	73.5%
A092040 Amicogen	1.3x	n/a	US$144.60m

No more companies

Price-To-Sales vs Industry: A092040 is good value based on its Price-To-Sales Ratio (1.3x) compared to the KR Biotechs industry average (9.2x).

Price to Sales Ratio vs Fair Ratio

What is A092040's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A092040 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1.3x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A092040's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Bioneer

₩513.9b

Operates as a biotechnology company in South Korea, the Americas, Europe, Asia, Africa, and internationally.

A064550

₩19,910.00

-0.7%

-34.6%

J2KBIO

₩52.5b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,180.00

-4.8%

n/a

Medy-Tox

₩867.0b

Operates as a biopharmaceutical company in South Korea.

A086900

₩128,800.00

2.1%

-41.2%